| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| EXELExelixis, Inc. | 11.81B | 44.06 | 15.85 | 6.98% | 29.63% | 31.37% | 7.49% | 0.08 |
| INCYIncyte Corporation | 20.1B | 101.27 | 15.80 | 21.22% | 25.03% | 24.9% | 6.74% | 0.01 |
| GMABGenmab A/S | 18.13B | 29.44 | 15.36 | 30.67% | 46.8% | 114.25% | 6.6% | 0.03 |
| SNDXSyndax Pharmaceuticals, Inc. | 1.89B | 21.71 | -5.82 | -279.31% | -269.93% | 1.20 | ||
| RCUSArcus Biosciences, Inc. | 2.55B | 20.37 | -6.19 | -4.26% | -142.91% | -55.94% | 0.16 | |
| RLAYRelay Therapeutics, Inc. | 1.78B | 10.26 | -6.37 | 53.44% | -18.01% | -48.76% | 0.06 | |
| STROSutro Biopharma, Inc. | 1.74B | 20.47 | -6.92 | -59.64% | -205.18% | -234.19% | 4.57 | |
| OLMAOlema Pharmaceuticals, Inc. | 1.66B | 24.20 | -11 | -48.77% | 0.00 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 43.36K | 3.52K | 8.48M | 7.76M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 0 | 0 | 56.29M | 73.11M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -43.36K | -3.52K | -64.77M | -80.86M |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | 91.88% | -1839985.23% | -24.84% |
| EBITDA | -43.36K | -3.52K | -64.68M | -80.66M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | 91.88% | -1837371.59% | -24.7% |
| D&A (Non-Cash Add-back) | 0 | 0 | 92K | 208K |
| EBIT | -43.36K | -3.52K | -64.77M | -80.86M |
| Net Interest Income | 0 | 0 | 0 | 8.46M |
| Interest Income | 0 | 0 | 0 | 8.46M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 72K | 6.59M |
| Pretax Income | -43.36K | -3.52K | -64.7M | -74.28M |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% |
| Net Income | -43.36K | -3.52K | -64.7M | -74.28M |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | 91.88% | -1837939.77% | -14.8% |
| Net Income (Continuing) | -43.36K | -3.52K | -64.7M | -74.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | 0.00 | -0.00 | 0.46 |
| EPS Growth % | - | - | - | - |
| EPS (Basic) | -0.00 | 0.00 | -0.00 | 0.46 |
| Diluted Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M |
| Basic Shares Outstanding | 20.48M | 20.48M | 20.48M | 16.64M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 0 | 0 | 0 | 1.95M |
| Cash & Short-Term Investments | 0 | 0 | 0 | 1.7M |
| Cash Only | 0 | 0 | 0 | 1.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 144.28K | 144.58K | 332.89K | 192.47M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 192.45M |
| Other Non-Current Assets | 144.28K | 144.58K | 332.89K | 25.13K |
| Total Assets | 144.28K | 144.58K | 332.89K | 194.42M |
| Asset Turnover | - | - | - | - |
| Asset Growth % | - | 0.21% | 130.25% | 58304.24% |
| Total Current Liabilities | 162.64K | 166.46K | 396.46K | 187.51K |
| Accounts Payable | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - |
| Short-Term Debt | 36.96K | 43.11K | 70.09K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 |
| Current Ratio | - | - | - | 10.40x |
| Quick Ratio | - | - | - | 10.40x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 5.52M |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 5.52M |
| Total Liabilities | 162.64K | 166.46K | 396.46K | 5.71M |
| Total Debt | 36.96K | 43.11K | 70.09K | 0 |
| Net Debt | 36.96K | 43.11K | 70.09K | -1.7M |
| Debt / Equity | - | - | - | - |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | - | - | - | - |
| Total Equity | -18.36K | -21.88K | -63.57K | 188.72M |
| Equity Growth % | - | -19.18% | -190.57% | 296969.04% |
| Book Value per Share | -0.00 | -0.00 | -0.00 | 11.34 |
| Total Shareholders' Equity | -18.36K | -21.88K | -63.57K | 188.72M |
| Common Stock | 288 | 288 | 460 | 192.45M |
| Retained Earnings | -43.36K | -46.88K | -88.57K | -3.73M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | 0 | 0 | 0 | -763.82K |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | - | - | - |
| Net Income | -74 | -3.52K | -41.69K | 7.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | -8.53M |
| Working Capital Changes | 0 | 0 | 15K | -104.61K |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 172.51K |
| Cash from Investing | 0 | 0 | 0 | -184M |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 0 | 0 | 186.46M |
| Debt Issued (Net) | 0 | 0 | 0 | -209.85K |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | -578.55K |
| Net Change in Cash | 0 | 0 | 0 | 1.7M |
| Free Cash Flow | 0 | 0 | 0 | -763.82K |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | - | - | - |
| FCF per Share | - | - | - | -0.05 |
| FCF Conversion (FCF/Net Income) | - | - | - | 0.01x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -78.74% |
| Return on Invested Capital (ROIC) | - | -13.26% | -350050.44% | -64.85% |
| FCF Conversion | - | - | - | 0.01x |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics